Dominantly inherited alzheimer network trial: an opportunity to prevent dementia
The conditions are Alzheimers Disease, Dementia, Alzheimers Disease, Familial.
The trial officially began on the December 22, 2021 and is planned to complete on October 2027.
To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.
Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc are the collaborators in this clinical trial.
The link to the complete study profile:
https://ichgcp.net/clinical-trials-registry/NCT05269394
or
